JNNP:APOEɛ4剂量与通过血脑屏障功能障碍增加脑铁和β-淀粉样蛋白相关

2022-06-13 网络 网络

阿尔茨海默病(AD)是最常见的痴呆类型,分为早发性AD和晚发性AD。 这两种形式AD的特点都是β-淀粉样蛋白(Aβ)过度积累。早发性AD相关基因突变的个体表现出Aβ的产生

阿尔茨海默病(AD)是最常见的痴呆类型,分为早发性AD和晚发性AD。 这两种形式AD的特点都是β-淀粉样蛋白(Aβ)过度积累。早发性AD相关基因突变的个体表现出Aβ的产生增加和清除减少,而晚发性AD患者(占95%以上的病例)仅表现出Aβ清除减少。APOE基因的ε4等位基因是晚发性AD最强和最有效的遗传风险因素。以前的研究表明,携带一个APOEε4等位基因(杂合子)会使晚发性AD的风险增加三到四倍,携带两个APOEε4等位基因(纯合子)会使风险增加9到15倍。考虑到发病率和风险决定效应,对APOEɛ4相关病理生理学的进一步了解将有助于开发晚发性AD的新治疗策略。载脂蛋白Eɛ4直接损害血脑屏障(BBB),这是一种由毛细血管内皮细胞、星形胶质细胞末梢和嵌入基底膜的周细胞形成的高度选择性半透性边界,可防止循环血液中的溶质非选择性地进入大脑。BBB也属于胶质系统和壁内动脉周围引流通路,参与通过基底膜清除中枢神经系统间质溶质。星形胶质细胞分泌的ApoE4诱导维持BBB完整性的脑毛细血管周细胞变性,携带APOEɛ4的个体表现出BBB功能障碍,导致认知能力下降,与AD病理无关。

目前的研究旨在验证载脂蛋白Eɛ4对有效BBB清除率的影响,使用先进的磁共振扩散制备的动脉自旋标记(DP-ASL)技术进行评估。 DP-ASL技术的一个吸引人的特点是其无创性,并且能够使用传统的3.0 T MRI系统。到目前为止,静脉注射钆基造影剂的动态增强MRI常用于测量BBB通透性(Ktrans指数)。值得注意的是,就功能性BBB指标而言,kw和Ktrans指数所反映的内容存在明显差异。在一个老年队列中,kw和Ktrans值之间的直接比较显示,白质、尾状核和大脑中动脉穿支区域存在显著相关性,但在其他区域不存在显著相关性。较高的Ktrans值反映BBB故障加速,而较低的kw值表明BBB相关的清除功能恶化。首先,本文介绍了阿尔茨海默病连续性队列早期APOEɛ4非携带者、杂合子和纯合子组的临床特征和神经心理学评分。其次,比较了AD相关的成像生物标志物,包括BBB-kw图、定量敏感性图(QSM)、[11C]匹兹堡复合B-正电子发射断层扫描(PiB-PET)和皮质厚度。最后,评估了kw值与AD病理学神经影像学指标和神经心理学评分的相关性本文发表在《神经病学,神经外科学和精神病学杂志》上().

在这项单中心观察性前瞻性队列研究中,使用扩散制备的动脉自旋标记扫描了24个APOEɛ4非携带者、22个杂合子和20个阿尔茨海默病连续体早期的纯合子,该标记估计了整个BBB的水交换率(kw)。参与者还接受了定量敏感性标测、[11C]匹兹堡化合物B-正电子发射断层扫描和神经心理学测试。使用基于图谱的方法,比较了各组的全脑区域kw,并分析了其与神经放射学和神经心理学发现的相关性。招募了24名APOEɛ4非携带者(APOEɛ3/ɛ3;11名男性和13名女人。使用简易精神状态检查(MMSE)和蒙特利尔认知评估(MoCA)对认知功能进行全面评估。MoCA包括注意力、视觉空间、言语和视觉记忆测试,已被证实是阿尔茨海默病连续体早期使用的敏感和有效的筛查工具。此外,还详细测量了与AD相关的情景记忆和执行功能认知领域。前者包括韦氏记忆量表修订版中的逻辑记忆故事回忆任务(逻辑记忆I:即时回忆;逻辑记忆II:延迟回忆)和Rey听觉语言学习测试。后者包括试验和反向数字跨度测试

磁共振图像

采用PCR扩增技术测定APOE基因型,使用3.0软件对每位参与者进行MRI扫描 T MRI系统(Ingenia,Philips Healthcare,Best,the Netherlands)配备32通道头部线圈。使用以下参数运行3D磁化制备的损坏turbo多梯度回波序列,该序列具有QSM(MP-QSM)的反转脉冲,用于3D T1加权和多回波相位图像:回波时间(TE)=6.0–31.0 ms,间隔6.2 ms,重复时间(TR)=35 ms,翻转角度(FA)=15°,反转时间=1200 ms,放炮间隔=2400 ms,turbo系数=62,视野(FOV)=192×192×140 mm3,切片厚度=1 mm。 然后,如前所述,从多回波相位图像重建每个参与者的QSM。

BBB kw、QSM值之间的偏相关分析

各组间新皮质的BBB kw值存在显著差异(APOEɛ4非携带者>杂合子>纯合子)。这些值与脑铁水平相关(额叶:r=−0.476,95%可信区间=−0.644至−0.264,p=0.011;内侧颞叶:r=−0.455, 95% CI=−0.628至−0.239,p=0.017),β-淀粉样蛋白负荷(额叶:r=−0.504, 95% CI公司=−0.731至−0.176,p=0.015;内侧颞叶:r=−0.452, 调整年龄、性别和APOEɛ4剂量后,神经心理学得分为0.110,p=0.036)。与先前显示脑小血管疾病中BBB改变与临床恶化平行的数据一致,在调整年龄、性别和APOEɛ4剂量后,证实额叶/内侧颞叶的kw与执行/记忆功能之间存在显著差异。值得注意的是,由毛细血管中星形胶质细胞分泌的ApoE4引起的BBB损伤的病理机制与脑小血管病相似,脑小血管病是由于BBB破坏导致脑内发生铁渗漏。载脂蛋白Eɛ4携带者自身的BBB清除功能障碍可能与过量的铁和aβ负荷起协同作用,从而激发导致AD病理学的关键病理生理过程。然而,载脂蛋白E基因型与脑铁状态之间的关联仍不明确。使用7.0的神经影像学研究 MRI系统发现载脂蛋白Eɛ4与较高的QSM值相关,而神经病理学研究未发现载脂蛋白Eɛ4与脑铁组织相关。

结果表明,APOEɛ4剂量增加与通过BBB清除有效脑废物(如铁和β-淀粉样蛋白)减少有关。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022479, encodeId=156b20224e9e1, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Thu Sep 15 14:16:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262393, encodeId=d884126239384, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421449, encodeId=5bdf1421449ad, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422655, encodeId=e4ee1422655c6, content=<a href='/topic/show?id=95b21919339' target=_blank style='color:#2F92EE;'>#β-淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19193, encryptionId=95b21919339, topicName=β-淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf1e3728410, createdName=jiekemin, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442909, encodeId=62d2144290905, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590630, encodeId=ee66159063057, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022479, encodeId=156b20224e9e1, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Thu Sep 15 14:16:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262393, encodeId=d884126239384, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421449, encodeId=5bdf1421449ad, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422655, encodeId=e4ee1422655c6, content=<a href='/topic/show?id=95b21919339' target=_blank style='color:#2F92EE;'>#β-淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19193, encryptionId=95b21919339, topicName=β-淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf1e3728410, createdName=jiekemin, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442909, encodeId=62d2144290905, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590630, encodeId=ee66159063057, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022479, encodeId=156b20224e9e1, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Thu Sep 15 14:16:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262393, encodeId=d884126239384, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421449, encodeId=5bdf1421449ad, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422655, encodeId=e4ee1422655c6, content=<a href='/topic/show?id=95b21919339' target=_blank style='color:#2F92EE;'>#β-淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19193, encryptionId=95b21919339, topicName=β-淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf1e3728410, createdName=jiekemin, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442909, encodeId=62d2144290905, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590630, encodeId=ee66159063057, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022479, encodeId=156b20224e9e1, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Thu Sep 15 14:16:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262393, encodeId=d884126239384, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421449, encodeId=5bdf1421449ad, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422655, encodeId=e4ee1422655c6, content=<a href='/topic/show?id=95b21919339' target=_blank style='color:#2F92EE;'>#β-淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19193, encryptionId=95b21919339, topicName=β-淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf1e3728410, createdName=jiekemin, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442909, encodeId=62d2144290905, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590630, encodeId=ee66159063057, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022479, encodeId=156b20224e9e1, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Thu Sep 15 14:16:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262393, encodeId=d884126239384, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421449, encodeId=5bdf1421449ad, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422655, encodeId=e4ee1422655c6, content=<a href='/topic/show?id=95b21919339' target=_blank style='color:#2F92EE;'>#β-淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19193, encryptionId=95b21919339, topicName=β-淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf1e3728410, createdName=jiekemin, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442909, encodeId=62d2144290905, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590630, encodeId=ee66159063057, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2022479, encodeId=156b20224e9e1, content=<a href='/topic/show?id=5b4d4e717dd' target=_blank style='color:#2F92EE;'>#屏障功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47717, encryptionId=5b4d4e717dd, topicName=屏障功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Thu Sep 15 14:16:55 CST 2022, time=2022-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262393, encodeId=d884126239384, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421449, encodeId=5bdf1421449ad, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422655, encodeId=e4ee1422655c6, content=<a href='/topic/show?id=95b21919339' target=_blank style='color:#2F92EE;'>#β-淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19193, encryptionId=95b21919339, topicName=β-淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf1e3728410, createdName=jiekemin, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442909, encodeId=62d2144290905, content=<a href='/topic/show?id=e112659308a' target=_blank style='color:#2F92EE;'>#淀粉样蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65930, encryptionId=e112659308a, topicName=淀粉样蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1774999170, createdName=ms7405317358118777, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590630, encodeId=ee66159063057, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Jun 10 14:16:55 CST 2022, time=2022-06-10, status=1, ipAttribution=)]
    2022-06-10 xiongke016

相关资讯

BMJ:这几种健康生活方式,可以延长5年寿命,预防阿尔茨海默病

这项研究表明,健康的饮食、阅读、定期运动锻炼、不吸烟、限制饮酒这些健康的生活方式,与男性和女性更长的预期寿命有关,并且能够显著减少他们将来患阿尔茨海默病的风险。

Alzheimers Res Ther:韩璎教授团队发现肠道菌群联合血浆Aβ可作为识别AD临床前期的潜在标记物

近日,由国家老年疾病临床医学研究中心(宣武医院)-中国AD临床前期联盟、首都医科大学宣武医院神经内科韩璎教授团队在国际学术期刊Alzheimers Research & Therapy发表题为

绿谷制药GV-971治疗阿尔茨海默病国际多中心III期临床停止

据Endpoints News报道,绿谷制药的阿尔茨海默病(AD)药物GV-971(甘露特钠胶囊,商品名:九期一)的国际III期临床试验已经停止。其中已有5家临床试验中心证实了该消息。

Neuropsychol Rev:认知干预是否可改善老年阿尔茨海默病患者的认知功能?

阿尔茨海默病(AD)是一种退行性的神经系统疾病,会逐渐影响到记忆、执行功能、视觉空间能力、注意力和其他认知功能,是老年人中最常见的痴呆形式。

核酸治疗: miR-23b-3p是一个有希望的阿尔茨海默病治疗靶点

研究者在体外和体内的研究结果提供了证据,表明miR-23b-3p通过减少tau过度磷酸化导致的细胞凋亡而在AD中发挥保护作用。

JNNP:血清GFAP鉴别阿尔茨海默病和额颞叶痴呆并预测MCI到痴呆的转化

反应性星形胶质细胞增生等神经炎症过程是包括阿尔茨海默病(AD)和额颞叶痴呆(FTD)在内的神经退行性痴呆的常见特征。在AD和FTD的死后脑组织和动物模型中发现了反应性星形胶质细胞,但它们在病理生理学中

拓展阅读

Eur J Prev Cardiol:南京医科大学:载脂蛋白A水平越高,心血管死亡率越低!

该研究发现脂蛋白水平与心血管疾病和全因死亡率有关。研究结果加强了脂蛋白水平与心脏健康之间关系的证据,并为调节脂蛋白水平以促进心脏健康提供了更加清晰的思路和策略。

南医大团队:超15万人研究,这种载脂蛋白水平越高,心血管死亡风险或越低

研究表明ApoA和ApoB水平与心血管死亡率存在相关性,且ApoB/ApoA 1比值升高是心血管死亡率和全因死亡率升高的危险因素。

Mol Psychiatry:深度研究载ApoE亚型对AD和PTSD风险的影响

人类载脂蛋白E(ApoE)亚型对依赖于年龄、性别和ApoE亚型的IEG信号变化的影响的研究结果。

Clin Trans Gastroenterology:晚期肝纤维化患者中脂蛋白 (a) 水平可以预测早期颈动脉粥样硬化

非酒精性脂肪性肝病(NAFLD)是指除外酒精和其他明确的损肝因素所致的肝细胞内脂肪过度沉积为主要特征的临床病理综合征,与胰岛素抵抗和遗传易感性密切相关的获得性代谢疾病。

Cardiovasc Diabetol:与糖尿病前期个体发展成2型糖尿病风险相关的血浆载脂蛋白

血清apoE水平与糖尿病前期个体进展成2型糖尿病的风险呈正相关

JNNP:较高的血液高密度脂蛋白和载脂蛋白A1水平与肌萎缩侧索硬化风险降低相关

除了占不到15%病例的少数单基因变异外,神经退行性疾病肌萎缩侧索硬化症(ALS)发展的确切因素尚不清楚。目前主要理论有:神经毒性物质累积;自由基使神经细胞膜受损;神经生长因子缺乏,使神经细胞无法持续生